BaseLaunch, a prominent platform for launching and funding early biotech ventures, has announced the addition of Takeda as its latest pharmaceutical partner, increasing its partner count to six. This strategic collaboration allows Takeda to tap into high-quality life sciences deal flow in Central Europe while contributing its expertise in biotech innovation and medicine development.
Stephan Emmerth, Director of BaseLaunch, expressed enthusiasm about the partnership, emphasizing its potential to significantly enhance the prospects of early-stage biotech ventures. Since its founding in 2018, BaseLaunch has successfully supported 27 biotech companies, with several advancing to Phase II clinical trials and securing over $1 billion in funding. Notably, the incubator has achieved two successful exits, including the $500 million acquisition of T3 Pharma by Boehringer Ingelheim.
Alison Handley, Head of the Center for External Innovation at Takeda, highlighted the partnership as a means to strengthen Takeda’s ties to European biotech innovation. By joining the investment board, Takeda aims to leverage its expertise to guide the creation of new therapies. The collaboration underscores the growing network of leading pharmaceutical companies involved with BaseLaunch, which also includes AbbVie, Roche, Novo Nordisk, Johnson & Johnson, and CSL, further solidifying Basel’s reputation as a hub for biopharma innovation.
Get started today with Solo access →
